Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

Stopped early

Conditions studied: Prostate Cancer

In brief

This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.

Key facts

Study ID

NCT05995236

Run by

Methodist Health System

People needed

35

Starts

2023-08-03

Expected to finish

2026-07-09

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 1. >18 years of age
• 2. Diagnosed with PSMA-positive metastatic castration-resistant prostate cancer and - has consented to undergo PSMA nuclear therapy per the treating physician. Specifically:
• Metastatic or Locally Advanced AND Inoperable
• Clear disease progression on PSMA-PET/CT
• PSMA-PET/CT scan positive disease within 6 weeks
• Labs:
• Hemoglobin: >8 g/dL
• White blood cell count: >2K cells/µL
• Platelet (Thrombocyte) count: >75 x 109/L
• No prior therapy with Radium-223 Dichloride

You may not qualify if…

• Patients who do not meet the Inclusion Criteria laid out in section 4.2 will be excluded from the study.

Where it is running

• Methodist Dallas Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.